


Claims

What is claimed is:

1. A compound of formula I:




or a pharmaceutically acceptable salt thereof, wherein:




- A is O,
NH, or
S;

- B is
C(=O)R₁,
C(=S)R₁,
heterocylco,
heteroaryl,
C(=O)-heterocyclo,
C(=N)-CN, or
C(=O)-heteteroaryl;

either D is N, E is C, and F is CH when "-----" is a bond, or D is CH, E is N, and F is CH₂ when "-----" is absent;

P is





, wherein “~~~~~” indicates the point of attachment;

5 J, K, Q independently are CR₂ or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR₂;

“-----” is absent; or is a bond; and

X, Y, Z independently are C=C-R₅,

10 O=C,
CH₂,
CHR₃,
CHR₄,
CR₃R₄,
NR₅,
15 N(C=O)R₅,
N(C=O)OR₅,
NSO₂R₅,
NSO₂NR₅,
O,
20 S,
SO, or
SO₂;

R₁ is H,

25 (C₁-C₈)alkyl,
(C₃-C₆)cycloalkyl,
O—(C₁-C₄)alkyl,

O—(C₃-C₆)cycloalkyl,
S—(C₁-C₄) alkyl,
S—(C₃-C₆)cycloalkyl,
NH₂,
5 NH(C₁-C₄)alkyl,
N((C₁-C₄)alkyl)₂, or
NH—(C₃-C₆)cycloalkyl;


R₂ is H,
10 halo,
(C₁-C₈)alkyl,
(C₃-C₆)cycloalkyl,
O—(C₁-C₄)alkyl,
O—(C₃-C₆)cycloalkyl,
15 S—(C₁-C₄) alkyl,
S—(C₃-C₆)cycloalkyl,
NH₂,
NH(C₁-C₄)alkyl,
N((C₁-C₄)alkyl)₂, or
20 NH—(C₃-C₆)cycloalkyl;

R₃ and R₄ independently are halo,
(C₁-C₈)alkyl,
(C₃-C₆)cycloalkyl,
25 O—(C₁-C₄)alkyl,
O—(C₃-C₆)cycloalkyl,
S—(C₁-C₄) alkyl,
S—(C₃-C₆)cycloalkyl,
NH₂,
30 NH(C₁-C₄)alkyl,
N((C₁-C₄)alkyl)₂,
NH—(C₃-C₆)cycloalkyl;

aryl,
 $(\text{CH}_2)_n$ -aryl,
heterocyclo,
 $(\text{CH}_2)_n$ -heterocyclo,
heteroaryl, or
 $(\text{CH}_2)_n$ -heteroaryl,
wherein n is 0, 1, 2, or 3;


R_5 is H,
 $(\text{C}_1\text{-C}_8)$ alkyl,
 $(\text{C}_3\text{-C}_6)$ cycloalkyl,
aryl,
 $(\text{CH}_2)_n$ -aryl,
heterocyclo,
 $(\text{CH}_2)_n$ -heterocyclo,
heteroaryl, or
 $(\text{CH}_2)_n$ -heteroaryl,
wherein n is as defined above.

2. The compound of claim 1 as designated in formula IA.




IA

3. The compound of claim 1 as designated in formula IB.







IB

4. The compound of claim 1 as designated in formula IC.



5




5. The compound of claim 1, wherein P is




10

wherein “~~~~~” indicates the point of attachment, J_a is N or CR’,
wherein R’ is H or F

6. The compound of claim 1, wherein P is



15



7. The compound of claim 6, wherein two of X, Y, or Z is C=C-R₅,

O=C,

5

NR₅,

N(C=O)R₅,

N(C=O)OR₅,

NSO₂R₅,

NSO₂NR₅,

10

O,

S,



SO, or

SO₂NR₅,


and the other of X, Y, or Z is CH₂ or CR₃R₄.

15

8. The compound of claim 7, wherein P is





, or




20




9. The compound of claim 7, wherein P is



, or



10. The compound of claim 7, wherein P is



11. The compound of claim 6, wherein one of X, Y, or Z is C=C-R₅,

O=C,

NR₅,

N(C=O)R₅,

N(C=O)OR₅,

NSO₂R₅,

NSO₂NR₅,

O,



S,


SO, or

SO₂NR₅,


and the other of X, Y, or Z is CH₂.

12. The compound of claim 11, wherein P is





5 13. A compound of formula II



II

or a pharmaceutically acceptable salt thereof, wherein:

10

A is O,

NH, or

S;

B is

15

C(=O)R₁,

C(=S)R₁,

heterocylco,

heteroaryl,

C(=O)-heterocyclo,

20

C(=N)-CN, or

C(=O)-heteteroaryl;

either D is N, E is C, and F is CH when "-----" is a bond, or D is CH, E is N, and F is CH₂ when "-----" is absent;

J, K, Q independently are CR_2 or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR_2 ;

“-----” is absent; or is a bond; and

5 X, Y, Z independently are $\text{C}=\text{C}-\text{R}_5$,

$\text{O}=\text{C}$,

CH_2 ,

CHR_3 ,

CHR_4 ,

10 CR_3R_4 ,

NR_5 ,

$\text{N}(\text{C}=\text{O})\text{R}_5$,

$\text{N}(\text{C}=\text{O})\text{OR}_5$,

NSO_2R_5 ,

15 NSO_2NR_5 ,

O,

S,

SO, or

SO₂;

20

R_1 is H,

$(\text{C}_1-\text{C}_8)\text{alkyl}$,

$(\text{C}_3-\text{C}_6)\text{cycloalkyl}$,

$\text{O}-(\text{C}_1-\text{C}_4)\text{alkyl}$,

25 $\text{O}-(\text{C}_3-\text{C}_6)\text{cycloalkyl}$,

$\text{S}-(\text{C}_1-\text{C}_4)\text{alkyl}$,

$\text{S}-(\text{C}_3-\text{C}_6)\text{cycloalkyl}$,

NH_2 ,

$\text{NH}(\text{C}_1-\text{C}_4)\text{alkyl}$,

30 $\text{N}((\text{C}_1-\text{C}_4)\text{alkyl})_2$, or

$\text{NH}-(\text{C}_3-\text{C}_6)\text{cycloalkyl}$,

R₂ is H,

halo,

(C₁-C₈)alkyl,

(C₃-C₆)cycloalkyl,

5 O—(C₁-C₄)alkyl,

O—(C₃-C₆)cycloalkyl,

S—(C₁-C₄) alkyl,

S—(C₃-C₆)cycloalkyl,

NH₂,

10 NH(C₁-C₄)alkyl,

N((C₁-C₄)alkyl)₂, or

NH—(C₃-C₆)cycloalkyl;

R₃ and R₄ independently are halo,

15 (C₁-C₈)alkyl,

(C₃-C₆)cycloalkyl,

O—(C₁-C₄)alkyl,

O—(C₃-C₆)cycloalkyl,

S—(C₁-C₄) alkyl,

20 S—(C₃-C₆)cycloalkyl,

NH₂,

NH(C₁-C₄)alkyl,

N((C₁-C₄)alkyl)₂,

NH—(C₃-C₆)cycloalkyl;

25 aryl,

(CH₂)_n-aryl,

heterocyclo,

(CH₂)_n-heterocyclo,

heteroaryl, or

30 (CH₂)_n-heteroaryl,

wherein n is 0, 1, 2, or 3;

R₅ is H,

(C₁-C₈)alkyl,

(C₃-C₆)cycloalkyl,

aryl,

5

(CH₂)_n-aryl,

heterocyclo,

(CH₂)_n-heterocyclo,


heteroaryl, or

(CH₂)_n-heteroaryl,

10

wherein n is as defined above.


13. The compound of claim 12 as designated in formula IIA.



IIA


15

14. The compound of claim 12 as designated in formula IIB.




IIB

- 20 15. The compound of claim 12 as designated in formula IIC.



IIC


16. The compound of claim 12 as designated in formula IID.



IID

wherein J_a is N or CR_6 , wherein R_6 is H or F.

17. The compound of claim 12 as designated in formula IIE.



18. The compound of claim 17, wherein two of X, Y, or Z is $C=C-R_5$,

$O=C$,

NR_5 ,

$N(C=O)R_5$,

$N(C=O)OR_5$,

NSO_2R_5 ,

NSO_2NR_5 ,

O,


S,

SO, or

SO₂NR₅,


and the other of X, Y, or Z is CH₂ or CR₃R₄.

- 5 19. The compound of claim 18 as designated in formula IIF.



IIF


20. The compound of claim 18 as designated in formula IIG.



IIG

10

21. The compound of claim 20 as designated in formula IIH.



IIH

15

22. The compound of claim 20, wherein one of X, Y, or Z is C=C-R₅,

O=C,

NR₅,

20

N(C=O)R₅,

N(C=O)OR₅,

NSO₂R₅,

NSO₂NR₅,

O,

S,


5

SO, or

SO₂NR₅,

and the others of X, Y, or Z is CH₂.

23. A compound of formula III



10

III

or a pharmaceutically acceptable salt thereof, wherein:

A is O,

15

NH, or

S;

B is C(=O)R₁,

C(=S)R₁,

20

heterocylco,

heteroaryl,

C(=O)-heterocyclo,

C(=N)-CN, or

C(=O)-heteteroaryl;

25

either D is N, E is C, and F is CH when “-----” is a bond, or D is CH, E is N, and F is CH₂ when “-----” is absent;

J, K, Q independently are CR_2 or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR_2 ;

“-----” is absent or is a bond;

5

X, Y, Z independently are $\text{C}=\text{C}-\text{R}_5$,

$\text{O}=\text{C}$,

CHR_3

CHR_4 ,

10

CR_3R_4 ,

NR_5 ,

$\text{N}(\text{C}=\text{O})\text{R}_5$,

$\text{N}(\text{C}=\text{O})\text{OR}_5$,

NSO_2R_5 ,

15

NSO_2NR_5 ,

O,

S,

SO, or

SO₂;

20

R_1 is H,

$(\text{C}_1-\text{C}_8)\text{alkyl}$,

$(\text{C}_3-\text{C}_6)\text{cycloalkyl}$,

$\text{O}-(\text{C}_1-\text{C}_4)\text{alkyl}$,

25

$\text{O}-(\text{C}_3-\text{C}_6)\text{cycloalkyl}$,

$\text{S}-(\text{C}_1-\text{C}_4)\text{alkyl}$,

$\text{S}-(\text{C}_3-\text{C}_6)\text{cycloalkyl}$,

NH_2 ,

$\text{NH}(\text{C}_1-\text{C}_4)\text{alkyl}$,

30

$\text{N}((\text{C}_1-\text{C}_4)\text{alkyl})_2$, or

$\text{NH}-(\text{C}_3-\text{C}_6)\text{cycloalkyl}$;

R₂ is H,

halo,
(C₁-C₈)alkyl,
(C₃-C₆)cycloalkyl,
5 O—(C₁-C₄)alkyl,
O—(C₃-C₆)cycloalkyl,
S—(C₁-C₄) alkyl,
S—(C₃-C₆)cycloalkyl,
NH₂,
10 NH(C₁-C₄)alkyl,
N((C₁-C₄)alkyl)₂, or
NH—(C₃-C₆)cycloalkyl;

R₃ and R₄ independently are H,

halo,
(C₁-C₈)alkyl,
(C₃-C₆)cycloalkyl,
O—(C₁-C₄)alkyl,
O—(C₃-C₆)cycloalkyl,
20 S—(C₁-C₄) alkyl,
S—(C₃-C₆)cycloalkyl,
NH₂,
NH(C₁-C₄)alkyl,
N((C₁-C₄)alkyl)₂,
25 NH—(C₃-C₆)cycloalkyl;
aryl,
(CH₂)_n-aryl,
heterocyclo,
(CH₂)_n-heterocyclo,
30 heteroaryl, or
(CH₂)_n-heteroaryl,

wherein n is 0, 1, 2, or 3;

R₅ is H,

(C₁-C₈)alkyl,

(C₃-C₆)cycloalkyl,

5 aryl,

(CH₂)_n-aryl,

heterocyclo,


(CH₂)_n-heterocyclo,

heteroaryl, or

10 (CH₂)_n-heteroaryl,


wherein n is as defined above.

24. The compound of claim 23 as designated in formula IIIA.



15 IIIA


25. The compound of claim 23 as designated in formula IIIB.



IIIB


20

26. The compound of claim 23 as designated in formula IIIC.



III C


27. The compound of claim 27 as designated in formula IIID.



II D

wherein J_a is N or CR_6 , wherein R_6 is H or F.

28. The compound of claim 27 as designated in formula IIIE.




IIIE

29. The compound of claim 28, wherein two of X, Y, or Z is $C=C-R_5$,
 $O=C$,
 NR_5 ,
 $N(C=O)R_5$,
 $N(C=O)OR_5$,
 NSO_2R_5 ,
 NSO_2NR_5 ,

O,
S,
SO, or
SO₂NR₅,

5 and the other of X, Y, or Z is CH₂ or CR₃R₄.


30. The compound of claim 29 as designated in formula IIIG.



IIIG

10

31. The compound of claim 29 as designated in formula IIIH.




IIIH

15 32. The compound of claim 28, wherein one of X, Y, or Z is C=C-R₅,

O=C,
NR₅,
N(C=O)R₅,
N(C=O)OR₅,
20 NSO₂R₅,
NSO₂NR₅,
O,
S,
SO, or

SO_2NR_5 ,
and the other of X, Y, or Z is CH_2 .

33. A compound of formula IV: ✓



IV

or a pharmaceutically acceptable salt thereof, wherein:

A is O,

NH, or

S;

B is

$\text{C}(=\text{O})\text{R}_1$,

$\text{C}(=\text{S})\text{R}_1$,

heterocylco,

heteroaryl,

$\text{C}(=\text{O})$ -heterocyclo,

$\text{C}(=\text{N})$ -CN, or

$\text{C}(=\text{O})$ -heteteroaryl;

either D is N, E is C, and F is CH when "-----" is a bond, or D is CH, E is N, and F is CH_2 when "-----" is absent;

J, K, Q independently are CR_2 or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR_2 ;

"-----" is absent; or is a bond; and

X, Y, Z independently are $\text{C}=\text{C}-\text{R}_5$,

| | |
|----|---|
| | O=C, |
| | CH ₂ , |
| | CHR ₃ , |
| | CHR ₄ , |
| 5 | CR ₃ R ₄ , |
| | NR ₅ , |
| | N(C=O)R ₅ , |
| | N(C=O)OR ₅ , |
| | NSO ₂ R ₅ , |
| 10 | NSO ₂ NR ₅ , |
| | O, |
| | S, |
| | SO, or |
| | SO ₂ ; |
| 15 | |
| | R ₁ is H, |
| | (C ₁ -C ₈)alkyl, |
| | (C ₃ -C ₆)cycloalkyl, |
| | O—(C ₁ -C ₄)alkyl, |
| 20 | O—(C ₃ -C ₆)cycloalkyl, |
| | S—(C ₁ -C ₄) alkyl, |
| | S—(C ₃ -C ₆)cycloalkyl, |
| | NH ₂ , |
| | NH(C ₁ -C ₄)alkyl, |
| 25 | N((C ₁ -C ₄)alkyl) ₂ , or |
| | NH—(C ₃ -C ₆)cycloalkyl, |
| | |
| | R ₂ is H, |
| | halo, |
| 30 | (C ₁ -C ₈)alkyl, |
| | (C ₃ -C ₆)cycloalkyl, |
| | O—(C ₁ -C ₄)alkyl, |

O—(C₃-C₆)cycloalkyl,
S—(C₁-C₄) alkyl,
S—(C₃-C₆)cycloalkyl,
NH₂,
5 NH(C₁-C₄)alkyl,
N((C₁-C₄)alkyl)₂, or
NH—(C₃-C₆)cycloalkyl;


R₃ and R₄ independently are halo,
10 (C₁-C₈)alkyl,
(C₃-C₆)cycloalkyl,
O—(C₁-C₄)alkyl,
O—(C₃-C₆)cycloalkyl,
S—(C₁-C₄) alkyl,
15 S—(C₃-C₆)cycloalkyl,
NH₂,
NH(C₁-C₄)alkyl,
N((C₁-C₄)alkyl)₂,
NH—(C₃-C₆)cycloalkyl;
20 aryl,
(CH₂)_n-aryl,
heterocyclo,
(CH₂)_n-heterocyclo,
heteroaryl, or
25 (CH₂)_n-heteroaryl,
wherein n is 0, 1, 2, or 3;

R₅ is H,
(C₁-C₈)alkyl,
30 (C₃-C₆)cycloalkyl,
aryl,
(CH₂)_n-aryl,

heterocyclo,
 $(CH_2)_n$ -heterocyclo,
heteroaryl, or
 $(CH_2)_n$ -heteroaryl,

5 wherein n is as defined above.


34. The compound of claim 33 as designated in formula IVA.



IVA

10


35. The compound of claim 33 as designated in formula IVB.



IVB


15

36. The compound of claim 33 as designated in formula IVC.



IVC

37. The compound of claim 33 as designated in formula IVD.




IVD

wherein J_a is N or CR_6 , wherein R_6 is H or F.

5

38. The compound of claim 33 as designated in formula IVE.



IVE

10 39. The compound of claim 38, wherein two of X, Y, or Z is $C=C-R_5$,

$O=C$,

NR_5 ,

$N(C=O)R_5$,

$N(C=O)OR_5$,

15

NSO_2R_5 ,

NSO_2NR_5 ,

O,

S,


SO, or

20

SO_2NR_5 ,


and the other of X, Y, or Z is CH_2 or CR_3R_4 .

40. The compound of claim 39 as designated in formula IVF.



IVF

41. The compound of claim 39 as designated in formula IVG.



IVH

42. The compound of claim 38, wherein one of X, Y, or Z is C=C-R₅,

O=C,

NR₅,

N(C=O)R₅,

N(C=O)OR₅,

NSO₂R₅,

NSO₂NR₅,

O,


S,

SO, or

SO₂NR₅,

and the others of X, Y, or Z is CH₂.

43. A compound of formula V



V

or a pharmaceutically acceptable salt thereof wherein:

5

A is O,

NH, or

S;

B is

10

C(=O)R₁,

C(=S)R₁,

heterocyclo,

heteroaryl,

C(=O)-heterocyclo,

15

C(=N)-CN, or

C(=O)-heteroaryl;

either D is N, E is C, and F is CH when "-----" is a bond, or D is CH, E is N, and F is CH₂ when "-----" is absent;

20

J, K, Q independently are CR₂ or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR₂;

"-----" is absent; or is a bond; and

X, Y, Z independently are C=C-R₅,

25

O=C,

CH₂,

CHR₃,

CHR₄,

| | |
|----|---|
| | CR ₃ R ₄ , |
| | NR ₅ , |
| | N(C=O)R ₅ , |
| | N(C=O)OR ₅ , |
| 5 | NSO ₂ R ₅ , |
| | NSO ₂ NR ₅ , |
| | O, |
| | S, |
| | SO, or |
| 10 | SO ₂ ; |
| | R ₁ is H, |
| | (C ₁ -C ₈)alkyl, |
| | (C ₃ -C ₆)cycloalkyl, |
| 15 | O—(C ₁ -C ₄)alkyl, |
| | O—(C ₃ -C ₆)cycloalkyl, |
| | S—(C ₁ -C ₄) alkyl, |
| | S—(C ₃ -C ₆)cycloalkyl, |
| | NH ₂ , |
| 20 | NH(C ₁ -C ₄)alkyl, |
| | N((C ₁ -C ₄)alkyl) ₂ , or |
| | NH—(C ₃ -C ₆)cycloalkyl, |
| | R ₂ is H, |
| 25 | halo, |
| | (C ₁ -C ₈)alkyl, |
| | (C ₃ -C ₆)cycloalkyl, |
| | O—(C ₁ -C ₄)alkyl, |
| | O—(C ₃ -C ₆)cycloalkyl, |
| 30 | S—(C ₁ -C ₄) alkyl, |
| | S—(C ₃ -C ₆)cycloalkyl, |
| | NH ₂ , |

NH(C₁-C₄)alkyl,
N((C₁-C₄)alkyl)₂, or
NH—(C₃-C₆)cycloalkyl;

5 R₃ and R₄ independently are halo,

(C₁-C₈)alkyl,
(C₃-C₆)cycloalkyl,
O—(C₁-C₄)alkyl,
O—(C₃-C₆)cycloalkyl,

10 S—(C₁-C₄) alkyl,
S—(C₃-C₆)cycloalkyl,
NH₂,

NH(C₁-C₄)alkyl,
N((C₁-C₄)alkyl)₂,
NH—(C₃-C₆)cycloalkyl;
aryl,

20 (CH₂)_n-aryl,
heterocyclo,
(CH₂)_n-heterocyclo,
heteroaryl, or
(CH₂)_n-heteroaryl,


wherein n is 0, 1, 2, or 3;

R_5 is H,

25 (C₁-C₈)alkyl,
(C₃-C₆)cycloalkyl,
aryl,
(CH₂)_n-aryl,
heterocyclo,
30 (CH₂)_n-heterocyclo,
heteroaryl, or
(CH₂)_n-heteroaryl,

wherein n is as defined above.


44. The compound of claim 43 as designated in formula VA.



5

VA


45. The compound of claim 43 as designated in formula VB.



VB


10

46. The compound of claim 43 as designated in formula VC.



VC


- 15 47. The compound of claim 43 as designated in formula VD



VD

wherein J_a is N or CR_6 , wherein R_6 is H or F.


- 5 48. The compound of claim 43 as designated in formula VE.



VE


49. The compound of claim 48, wherein two of X, Y, or Z is $C=C-R_5$,
 10 $O=C$,
 NR_5 ,
 $N(C=O)R_5$,
 $N(C=O)OR_5$,
 NSO_2R_5 ,
 15 NSO_2NR_5 ,
 O ,
 S ,
 SO , or
 SO_2NR_5 ,
 20 and the other of X, Y, or Z is CH_2 or CR_3R_4 .

50. The compound of claim 51 as designated in formula VF.



VF

53. The compound of claim 51 as designated in formula VG.



VG

- 5
54. The compound of claim 48, wherein one of X, Y, or Z is C=C-R₅,
O=C,
NR₅,
N(C=O)R₅,
10 N(C=O)OR₅,
NSO₂R₅,
NSO₂NR₅,
O,
S,
15 SO, or
SO₂NR₅,
and the others of X, Y, or Z is CH₂.

55. A compound which is:
20 (S)-N-[2-Oxo-3-(6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-
oxazolidin-5-ylmethyl]-acetamide;
(S)-N-[2-Oxo-3-(5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-
oxazolidin-5-ylmethyl]-acetamide;
25 (S)-N-[3-(6-Bromo-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-
2-oxo-oxazolidin-5-ylmethyl]-acetamide;
(S)-N-[3-(6-Dimethylaminomethylene-5-oxo-6,7,8,9-tetrahydro-5H-
30 benzocyclohepten-2-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[2-Oxo-3-(5-oxo-6-pyridin-4-ylmethylene-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-oxazolidin-5-ylmethyl]-acetamide;

5 (S)-N-[3-(6-Benzylidene-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-{3-[6-(4-Fluoro-benzylidene)-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide;

10 (S)-N-[2-Oxo-3-(5-oxo-6-thiophen-3-ylmethylene-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-oxazolidin-5-ylmethyl]-acetamide;

15 (S)-N-[3-(6-Furan-3-ylmethylene-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[2-Oxo-3-(6-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-oxazolidin-5-ylmethyl]-acetamide;

20 (S)-N-[2-Oxo-3-(7-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[2-Oxo-3-(8-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-oxazolidin-5-ylmethyl]-acetamide;

25 (S)-N-[2-Oxo-3-(9-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-oxazolidin-5-ylmethyl]-acetamide;

30 (S)-N-[3-(8,9-Dihydro-7H-benzocyclohepten-2-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(8,9-Dihydro-5H-benzocyclohepten-2-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

35 (S)-N-[3-(6,9-Dihydro-5H-benzocyclohepten-2-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(6,7-Dihydro-5H-benzocyclohepten-2-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

40 (S)-N-[2-Oxo-3-(2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-yl)-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[2-Oxo-3-(2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-yl)-oxazolidin-5-ylmethyl]-acetamide;

45 (S)-N-[2-Oxo-3-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-oxazolidin-5-ylmethyl]-acetamide;

- (S)-N-[2-Oxo-3-(2,3,4,5-tetrahydro-1H-benzo[c]azepin-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- 5 (S)-N-[2-Oxo-3-(2,3,4,5-tetrahydro-1H-benzo[b]azepin-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-[2-Oxo-3-(2,3,4,5-tetrahydro-benzo[b]oxepin-7-yl)-oxazolidin-5-ylmethyl]-acetamide;
- 10 (S)-N-[2-Oxo-3-(1,3,4,5-tetrahydro-benzo[c]oxepin-7-yl)-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-[2-Oxo-3-(5,6,8,9-tetrahydro-7-oxa-benzocyclohepten-2-yl)-oxazolidin-5-ylmethyl]-acetamide;
- 15 (S)-N-[2-Oxo-3-(1,3,4,5-tetrahydro-benzo[c]oxepin-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-[2-Oxo-3-(2,3,4,5-tetrahydro-benzo[b]oxepin-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- 20 (S)-N-[2-Oxo-3-(6,7,8,9-tetrahydro-5-oxa-7-aza-benzocyclohepten-2-yl)-oxazolidin-5-ylmethyl]-acetamide;
- 25 (S)-N-[2-Oxo-3-(2,3,4,5-tetrahydro-benzo[b]thiepin-7-yl)-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-[2-Oxo-3-(1,3,4,5-tetrahydro-benzo[c]thiepin-7-yl)-oxazolidin-5-ylmethyl]-acetamide;
- 30 (S)-N-[2-Oxo-3-(1,2,4,5-tetrahydro-benzo[d]thiepin-7-yl)-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-[2-Oxo-3-(1,3,4,5-tetrahydro-benzo[c]thiepin-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- 35 (S)-N-[2-Oxo-3-(2,3,4,5-tetrahydro-benzo[b]thiepin-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- 40 (S)-N-[2-Oxo-3-(5-oxo-2,3,4,5-tetrahydro-benzo[b]oxepin-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- (S)-N-[2-Oxo-3-(5-oxo-2,3,4,5-tetrahydro-benzo[b]thiepin-8-yl)-oxazolidin-5-ylmethyl]-acetamide;
- 45

(S)-N-[2-Oxo-3-(1,1,5-trioxo-2,3,4,5-tetrahydro-1H-116-benzo[b]thiepin-8-yl)-oxazolidin-5-ylmethyl]-acetamide;

5 (S)-N-[2-Oxo-3-(5-oxo-2,3,4,5-tetrahydro-benzo[b]oxepin-7-yl)-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(6,6-Difluoro-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

10 (S)-N-[3-(6-Benzylidene-5-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(2-Methyl-2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; or

15 (S)-N-[3-(3-Methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide.

56. A pharmaceutical formulation comprising a compound of claim 1 admixed
20 with a pharmaceutically acceptable diluent, carrier, or excipient.

57. A method of treating a bacterial infection in a mammal, comprising
administering to a mammal in need thereof an effective amount of a compound of
claim 1.

25